Profile | GDS2987 / GI_7705347-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 115.9 | 78 |
GSM215244 | HMVEC_vehicle_rep2 | 139 | 79 |
GSM215253 | HMVEC_vehicle_rep3 | 125.8 | 79 |
GSM215254 | HMVEC_atorvastatin_rep1 | 21.8 | 49 |
GSM215282 | HMVEC_atorvastatin_rep3 | 44.7 | 66 |
GSM215344 | HMVEC_atorvastatin_rep2 | 45.9 | 67 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 164.7 | 80 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 146.8 | 79 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 133.7 | 78 |
GSM215294 | HMVEC_SLx2119_rep1 | 78.1 | 75 |
GSM215295 | HMVEC_SLx2119_rep2 | 33.6 | 54 |
GSM215296 | HMVEC_SLx2119_rep3 | 44.4 | 58 |
GSM215297 | PASMC_vehicle_rep1 | 18.3 | 28 |
GSM215298 | PASMC_vehicle_rep2 | 1.1 | 2 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | ||
GSM215313 | PASMC_atorvastatin_rep3 | 13.6 | 21 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | ||
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | ||
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | 55.1 | 65 |
GSM215328 | PASMC_SLx2119_rep2 | ||
GSM215329 | PASMC_SLx2119_rep3 | 32.2 | 52 |
GSM215330 | Fibroblasts_vehicle_rep1 | 263.1 | 84 |
GSM215331 | Fibroblasts_vehicle_rep2 | 194.5 | 81 |
GSM215332 | Fibroblasts_vehicle_rep3 | 217.4 | 83 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 246.8 | 84 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 164.8 | 79 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 217.8 | 82 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 235.3 | 83 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 251.5 | 84 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 274.7 | 84 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 279.8 | 84 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 255.8 | 84 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 254.8 | 84 |